Other Clinical Trial - Oxford/AstraZeneca COVID-19 Vaccine Effectiveness

Status Completed

Clinical Trial Summary

This is a retrospective cohort study to assess the real world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death.

Clinical Trial Description

The United Kingdom (UK) is one of the first countries that introduced a mass vaccination campaign for COVID-19 and vaccination of the adult population first focused on the oldest age groups, their carers and health care workers (JCVI, 2020). Three COVID-19 vaccines were licensed and are being used including the Moderna, the BioNTech/Pfizer, and the Oxford/AstraZeneca vaccines. Vaccination with the BioNTech/Pfizer vaccine started in December 2020 and the Oxford/AstraZeneca vaccine started in early January 2021. This study is to primarily assess the effectiveness of the Oxford/AstraZeneca COVID-19 vaccine. Given the known high efficacy of the mRNA vaccines in randomized controlled trials (RCTs) and real-world evidence studies, the study aims also to evaluate the vaccine effectiveness (VE) of other COVID-19 vaccines as a validation of the study's methods. On 16 September 2021 it was announced that Booster doses would be introduced in the UK to address vaccine waning and for groups with a suboptimal response. Little is known about health care resource utilisation (HCRU) and health care costs for those who have had COVID-19 or by individual clinical risk group. The RAVEN study is a retrospective cohort study to assess the real-world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death. Analyses will examine the effectiveness of one and two doses, and booster or other additional doses if applicable. This study's extension (October 2021) adds a more detailed exploration of VE in risk groups and an evaluation of the HCRU by people with COVID-19 compared with those who are vaccinated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05047822
Study type	Observational
Source	AstraZeneca
Contact
Status	Completed
Phase
Start date	August 23, 2021
Completion date	January 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04997551` - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19	Phase 3
Recruiting	`NCT04977024` - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer	Phase 2
Completed	`NCT05049226` - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated	`NCT04455815` - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)	Phase 2
Completed	`NCT04662437` - The Status of Parathyroid Hormone Secretion in Covid-19 Patients
Recruiting	`NCT05792878` - Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Completed	`NCT04659200` - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting	`NCT04470583` - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn	`NCT04377568` - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children	Phase 2
Completed	`NCT04848610` - The Factors That Affect the Infection of COVID-19
Recruiting	`NCT04582903` - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Recruiting	`NCT06032000` - Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)	Phase 1
Terminated	`NCT04941703` - "CHANGE COVID-19 Severity"	Phase 1/Phase 2
Active, not recruiting	`NCT04639466` - A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection	Phase 1/Phase 2
Completed	`NCT04575038` - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19	Phase 2
Recruiting	`NCT05022446` - The Impact of COVID-19 on Pulmonary Procedures
Completed	`NCT04347798` - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Active, not recruiting	`NCT04650178` - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Recruiting	`NCT04169542` - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England — RAVEN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms